Signal active
Bio
Abbie Celniker joined Third Rock Ventures as Partner in 2016. Dr. Celniker brings more than 20 years of proven expertise in leading protein therapeutic discovery and development companies and programs to Eleven Biotherapeutics.
Prior to joining Eleven, Abbie was CEO of Taligen Therapeutics, a biotechnology company focused on complement system regulation, which was acquired by Alexion Pharmaceuticals in January 2011.
Prior to Taligen, Dr. Celniker was global head of biologics at Novartis, where she oversaw the biologics division, forged strategic alliances, and led internal discovery and development to build the pipeline.
Prior to Novartis, Dr. Celniker spent more than six years at Millennium Pharmaceuticals as senior vice president, R&D strategy and operations and head of biotherapeutics and pharmaceutical sciences.
Previously, she held senior research and development leadership roles with Wyeth BioPharma (Genetics Institute) and Genentech.
Dr. Celniker holds a Ph.D. in Molecular Biology from the University of Arizona and a B.A. in Biology from the University of California, San Diego.
Location
Boston, Massachusetts, United States, North America
Social
Primary Organization
2007
11-50
Biotechnology, Health Care, Clinical Trials, Health Diagnostics
Jobs history
4
Flare Therapeutics
Board Member
Invalid date - Current
Abata Therapeutics
Chairman of Board
Invalid date - Current
Flare Therapeutics
Interim Chief Executive Officer
Invalid date - 2022
Third Rock Ventures
Partner
2016 - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Abbie Celniker is the Chairman at ImaginAb, based in United States, North America. With a background in Biotechnology, Abbie Celniker has a rich history of leadership and innovation. Abbie Celniker studied BS Biology @ University of California, San Diego. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
3
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
May 13, 2021 | Flare Therapeutics | Series A - Flare Therapeutics | Third Rock Ventures | 82.0M |
Jun 23, 2021 | Abata Therapeutics | Series A - Abata Therapeutics | Third Rock Ventures | 95.0M |
Mar 22, 2023 | Flare Therapeutics | Series B - Flare Therapeutics | Third Rock Ventures | 123.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.